Molecular laboratory GENETWORx Laboratories stated on Monday that it is capable of delivering up to 150,000 COVID-19 tests per month as well as provide 24-hour turnaround results to assist the nation in the battle against the deadly virus.
The company will ship at least 800 COVID-19 tests a day with the ability to increase capacity to 5,000 tests per day and up to 150,000 per month during April. It can provide results from the GENETWORx COVID-19 tests to patients in 24 hours upon receipt of sample.
According to the company, the GENETWORx test follows the Centers for Disease Control (CDC) approved Assay kits required for sample testing for the Coronavirus genome. It is now working diligently to adapt their system to allow accurate, efficient testing of hundreds of samples for the COVID-19 genome in a few hours per run.
In addition, the company is working within the emergency use authorization guidelines from the United States Food and Drug Administration (FDA) to specifically conduct COVID-19 testing.
Due to the extreme nature of the COVID-19 emergency, the company has repurposed a portion of their lab so that rapid accurate analysis of COVID-19 samples can be performed in response to the national need.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT